FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

| | | | 01 3601 | 1011 30(11) 01 | the investment Company Act of 1 | 340 | | | | |
|--|----------------|---------------|---|--|--|--|---|--|--|--|
| 1. Name and Add ECHENBE | | 2 | 2. Date of Event Requiring Statement (Month/Day/Year) 05/26/2004 | | 3. Issuer Name and Ticker or Trading Symbol ANGIODYNAMICS INC [ANGO] | | | | | |
| (Last) (First) (Middle) 623 SYDENHAM AVE | | | | | 4. Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Own | | (Mc | Amendment, Date of Original Filed nth/Day/Year) | | |
| (Street) WESTMONT QUEBEC CANADA (City) | A8 (State) | H3Y 2Z3 (Zip) | | | Officer (give title below) | Other (spe below) | App | licable Line) C Form filed by | VGroup Filing (Check y One Reporting Person y More than One erson | |
| (City) | (State) | | | | | | | | | |
| Table I - Non-Derivative Securities Beneficially Owned | | | | | | | | | | |
| 1. Title of Security (Instr. 4) | | | | Amount of Securities an eneficially Owned (Instr. 4) are Form: Direct (D) or Indirect (I) (Instr. 5) | | t (D) (Inst | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 4) | | | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise | 5. Ownership Form: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | |
| | | | Date Exercisable | Expiratior Date | Title | Amount or Number of Shares | Price of Derivative Security | Direct (D) or Indirect (I) (Instr. 5) | | |
| Common stock | options (right | to buy) | (1) | 03/04/2007 | Common stock | 78,409 | 4.35 | D | | |
| Common stock | options (right | to buy) | (1) | 05/30/2008 | Common stock | 2,091 | 4.35 | D | | |
| Common stock | options (right | to buy) | (1) | 05/29/2009 | Common stock | 2,091 | 4.35 | D | | |
| Common stock | options (right | to buy) | (2) | 06/03/2010 | Common stock | 2,091 | 4.35 | D | | |
| Common stock | options (right | to buy) | (3) | 06/02/2011 | Common stock | 2,091 | 4.35 | D | | |
| Common stock | options (right | to buy) | (4) | 05/21/2012 | Common stock | 2,091 | 6.52 | D | | |
| Common stock | options (right | to buy) | (5) | 05/31/2013 | Common stock | 6,273 | 6.52 | D | | |

Explanation of Responses:

- 1. Exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders.
- 2. Options for 80% of the shares will become exercisable on the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders. Options for 20% of the shares will become exercisable on the later of 6/3/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders; provided, that if such distribution does not occur before 6/3/2005, then such options will become exercisable on 8/2/2005.
- 3. Options for 60% of the shares will become exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders. Options for 20% of the shares will become exercisable upon the later of 6/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders; provided, that if such distribution does not occur before 6/2/2005, then such options will become exercisable on 8/2/2005. Options for 20% of the shares will become exercisable on 6/2/2006.
- 4. Options for 40% of the shares will become exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders, Options for 20% of the shares will become exercisable upon the later of 5/21/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders; provided, that if such distribution does not occur by 5/21/2005, then such options will become exercisable on 8/2/2005. Options for 20% of the shares are each exercisable on 5/21/2006 and 5/21/2007, respectively.
- 5. Options for 20% of the shares will become exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. commmon stock to its stockholders. Options for 20% of the shares will become exercisable on the later of 5/31/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders; provided, that if such distribution does not occur before 5/3/2005, then such options will become exercisable on 8/2/2005. Options for 20% of the shares are each exercisable on 5/31/2006, 5/31/2007, and 5/31/2008, respectively.

Ronald F. Lamy as attorney in fact for Paul Echenberg

05/26/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Joseph G. Gerardi and Ronald F. Lamy, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of AngioDynamics, Inc., Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of May 2004.

/s/ Paul S. Echenberg _